Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth

Authors: Leila Haery, Julián G Lugo-Picó, Ryan A Henry, Andrew J Andrews, Thomas D Gilmore

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Recent genome-wide studies have shown that approximately 30% of diffuse large B-cell lymphoma (DLBCL) cases harbor mutations in the histone acetyltransferase (HAT) coactivators p300 or CBP. The majority of these mutations reduce or eliminate the catalytic HAT activity. We previously demonstrated that the human DLBCL cell line RC-K8 expresses a C-terminally truncated, HAT-defective p300 protein (p300ΔC-1087), whose expression is essential for cell proliferation.

Methods

Using results from large-scale DLBCL studies, we have identified and characterized a second C-terminally truncated, HAT-defective p300 mutant, p300ΔC-820, expressed in the SUDHL2 DLBCL cell line. Properties of p300ΔC-820 were characterized in the SUDHL2 DLBCL cell line by Western blotting, co-immunoprecipitation, and shRNA gene knockdown, as well by using cDNA expression vectors for p300ΔC-820 in pull-down assays, transcriptional reporter assays, and immunofluorescence experiments. A mass spectrometry-based method was used to compare the histone acetylation profile of DLBCL cell lines expressing various levels of wild-type p300.

Results

We show that the SUDHL2 cell line expresses a C-terminally truncated, HAT-defective form of p300 (p300ΔC-820), but no wild-type p300. The p300ΔC-820 protein has a wild-type ability to localize to subnuclear “speckles,” but has a reduced ability to enhance transactivation by transcription factor REL. Knockdown of p300ΔC-820 in SUDHL2 cells reduced their proliferation and soft agar colony-forming ability. In RC-K8 cells, knockdown of p300ΔC-1087 resulted in increased expression of mRNA and protein for REL target genes A20 and IκBα, two genes that have been shown to limit the growth of RC-K8 cells when overexpressed. Among a panel of B-lymphoma cell lines, low-level expression of full-length p300 protein, which is characteristic of the SUDHL2 and RC-K8 cells, was associated with decreased acetylation of histone H3 at lysines 14 and 18.

Conclusions

The high prevalence of p300 mutations in DLBCL suggests that HAT-deficient p300 activity defines a subtype of DLBCL, which we have investigated using human DLBCL cell lines RC-K8 and SUDHL2. Our results suggest that truncated p300 proteins contribute to DLBCL cell growth by affecting the expression of specific genes, perhaps through a mechanism that involves alterations in global histone acetylation.
Appendix
Available only for authorised users
Literature
1.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006, 107: 265-276. 10.1182/blood-2005-06-2508PubMedCentralCrossRefPubMed
2.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000, 403: 503-511. 10.1038/35000501CrossRefPubMed
3.
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R: Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011, 471: 189-195. 10.1038/nature09730PubMedCentralCrossRefPubMed
4.
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R: Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011, 43: 830-837. 10.1038/ng.892PubMedCentralCrossRefPubMed
5.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011, 476: 298-303. 10.1038/nature10351PubMedCentralCrossRefPubMed
6.
Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernandez-Lemus E, Schwarz-Cruz Y, Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012, 109: 3879-3884. 10.1073/pnas.1121343109PubMedCentralCrossRefPubMed
7.
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A: BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010, 120: 4569-4582. 10.1172/JCI42869.PubMedCentralCrossRef
8.
Giordano A, Avantaggiati ML: p300 and CBP: partners for life and death. J Cell Physiol. 1999, 181: 218-230. 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5CrossRefPubMed
9.
Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T: CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A. 1997, 94: 2927-2932. 10.1073/pnas.94.7.2927PubMedCentralCrossRefPubMed
10.
Garbati MR, Alço G, Gilmore TD: Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett. 2010, 291: 237-245. 10.1016/j.canlet.2009.10.018PubMedCentralCrossRefPubMed
11.
Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K: Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997, 89: 1175-1184. 10.1016/S0092-8674(00)80304-9CrossRefPubMed
12.
Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE: Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry. 2009, 48: 2115-2124. 10.1021/bi802055vPubMedCentralCrossRefPubMed
13.
Sartorelli V, Huang J, Hamamori Y, Kedes L: Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol. 1997, 17: 1010-1026.PubMedCentralCrossRefPubMed
14.
Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000, 6: 1335-1340. 10.1038/82146CrossRefPubMed
15.
Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM: CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci U S A. 2000, 97: 1020-1025. 10.1073/pnas.97.3.1020PubMedCentralCrossRefPubMed
16.
Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK: A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol. 1998, 18: 2218-2229.PubMedCentralCrossRefPubMed
17.
Abraham SE, Lobo S, Yaciuk P, Wang HG, Moran E: p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene. 1993, 8: 1639-1647.PubMed
18.
Garbati MR, Thompson RC, Haery L, Gilmore TD: A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett. 2011, 302: 76-83. 10.1016/j.canlet.2010.12.018PubMedCentralCrossRefPubMed
19.
Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T, Caldas C: Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000, 24: 300-303. 10.1038/73536CrossRefPubMed
20.
Ionov Y, Matsui S, Cowell JK: A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci U S A. 2004, 101: 1273-1278. 10.1073/pnas.0307276101PubMedCentralCrossRefPubMed
21.
Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL: Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood. 2009, 114: 4804-4812. 10.1182/blood-2009-04-217794CrossRefPubMed
22.
Eckner R, Yao TP, Oldread E, Livingston DM: Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev. 1996, 10: 2478-2490. 10.1101/gad.10.19.2478CrossRefPubMed
23.
Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung JU: Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol. 2000, 20: 8254-8263. 10.1128/MCB.20.21.8254-8263.2000PubMedCentralCrossRefPubMed
24.
Wang L, Grossman SR, Kieff E: Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A. 2000, 97: 430-435. 10.1073/pnas.97.1.430PubMedCentralCrossRefPubMed
25.
Cotter MA, Robertson ES: Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol. 2000, 20: 5722-5735. 10.1128/MCB.20.15.5722-5735.2000PubMedCentralCrossRefPubMed
26.
Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B: p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene. 2008, 27: 5717-5728. 10.1038/onc.2008.181CrossRefPubMed
27.
Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD: The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene. 2002, 21: 8759-8768. 10.1038/sj.onc.1206033CrossRefPubMed
28.
Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L: Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature. 2009, 459: 717-721. 10.1038/nature07968PubMedCentralCrossRefPubMed
29.
von Mikecz A, Zhang S, Montminy M, Tan EM, Hemmerich P: CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J Cell Biol. 2000, 150: 265-273. 10.1083/jcb.150.1.265PubMedCentralCrossRefPubMed
30.
Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JY, Graessmann A, Nakatani Y, Levrero M: Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell. 1997, 1: 35-45. 10.1016/S1097-2765(00)80005-2CrossRefPubMed
31.
Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature. 2004, 430: 694-699. 10.1038/nature02794CrossRefPubMed
32.
Krikos A, Laherty CD, Dixit VM: Transcriptional activation of the tumor necrosis factor α-inducible zinc finger protein, A20, is mediated by κB elements. J Biol Chem. 1992, 267: 17971-17976.PubMed
33.
Lim KH, Yang Y, Staudt LM: Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev. 2012, 246: 359-378. 10.1111/j.1600-065X.2012.01105.xPubMedCentralCrossRefPubMed
34.
Gilmore TD: Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999, 18: 6925-6937. 10.1038/sj.onc.1203222CrossRefPubMed
35.
Luebben WR, Sharma N, Nyborg JK: Nucleosome eviction and activated transcription require p300 acetylation of histone H3 lysine 14. Proc Natl Acad Sci U S A. 2010, 107: 19254-19259. 10.1073/pnas.1009650107PubMedCentralCrossRefPubMed
36.
Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ: Adenovirus small e1a alters global patterns of histone modification. Science. 2008, 321: 1084-1085. 10.1126/science.1155544PubMedCentralCrossRefPubMed
37.
Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK: Epigenetic reprogramming by adenovirus e1a. Science. 2008, 321: 1086-1088. 10.1126/science.1155546PubMedCentralCrossRefPubMed
38.
Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005, 435: 1262-1266. 10.1038/nature03672CrossRefPubMed
39.
Kueh AJ, Dixon MP, Voss AK, Thomas T: HBO1 is required for H3K14 acetylation and normal transcriptional activity during embryonic development. Mol Cell Biol. 2011, 31: 845-860. 10.1128/MCB.00159-10PubMedCentralCrossRefPubMed
40.
Love IM, Sekaric P, Shi D, Grossman SR, Androphy EJ: The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle. 2012, 11: 2458-2466. 10.4161/cc.20864PubMedCentralCrossRefPubMed
41.
Thompson RC, Vardinogiannis I, Gilmore TD: The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One. 2013, 8: e62822- 10.1371/journal.pone.0062822PubMedCentralCrossRefPubMed
42.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 1989, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2
43.
Starczynowski DT, Reynolds JG, Gilmore TD: Mutations of tumor necrosis factor α-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene. 2005, 24: 7355-7368. 10.1038/sj.onc.1208902CrossRefPubMed
44.
Sun CC, Thorley-Lawson DA: Plasma cell-specific transcription factor XBP-1 s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol. 2007, 81: 13566-13577. 10.1128/JVI.01055-07PubMedCentralCrossRefPubMed
45.
Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA, Denis GV: Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer. 2009, 124: 473-482. 10.1002/ijc.23946PubMedCentralCrossRefPubMed
46.
Liang M-C, Bardhan S, Porco JA, Gilmore TD: The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient diffuse large B-cell lymphoma cell line. Cancer Lett. 2006, 241: 69-78. 10.1016/j.canlet.2005.10.004CrossRefPubMed
47.
48.
Chin M, Herscovitch M, Zhang N, Waxman DJ, Gilmore TD: Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene. 2009, 28: 2100-2111. 10.1038/onc.2009.74PubMedCentralCrossRefPubMed
49.
Lee TI, Johnstone SE, Young RA: Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat Protoc. 2006, 1: 729-748. 10.1038/nprot.2006.98PubMedCentralCrossRefPubMed
50.
Amir-Zilberstein L, Ainbinder E, Toube L, Yamaguchi Y, Handa H, Dikstein R: Differential regulation of NF-κB by elongation factors is determined by core promoter type. Mol Cell Biol. 2007, 27: 5246-5259. 10.1128/MCB.00586-07PubMedCentralCrossRefPubMed
51.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262CrossRefPubMed
52.
Garcia BA, Mollah S, Ueberheide BM, Busby SA, Muratore TL, Shabanowitz J, Hunt DF: Chemical derivatization of histones for facilitated analysis by mass spectrometry. Nat Protoc. 2007, 2: 933-938. 10.1038/nprot.2007.106PubMedCentralCrossRefPubMed
53.
Kuo YM, Andrews AJ: Quantitating the specificity and selectivity of Gcn5-mediated acetylation of histone H3. PLoS One. 2013, 8: e54896- 10.1371/journal.pone.0054896PubMedCentralCrossRefPubMed
Metadata
Title
Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth
Authors
Leila Haery
Julián G Lugo-Picó
Ryan A Henry
Andrew J Andrews
Thomas D Gilmore
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-29

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in Nasopharyngeal Carcinoma via activation of NF-κB pathway

Research

IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9

Research

Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells

Research

SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1

Research

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

Research

Function of RasGRP3 in the formation and progression of human breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits